Physician profile
Jonathan A Summers
NPI 1487745691
$7,239.31
in general payments reported to CMS, 2019-2025
26 companies · $34.41 in 2025
The $34.41 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,119 · 2021: $1,983 · 2022: $2,103 · 2023: $1,919 · 2024: $80.13 · 2025: $34.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,033.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,420.74 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Lilly USA, LLC | $1,280.76 | 2020-2024 | Mounjaro, Emgality, Zepbound |
| Novo Nordisk INC | $793.39 | 2020-2023 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $647.70 | 2020-2024 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $522.84 | 2020-2023 | Otezla, Repatha, Aimovig |
| Biohaven Pharmaceutical Holding Company LTD. | $357.25 | 2022 | |
| Amarin Pharma, INC. | $337.52 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $303.66 | 2020-2021 | |
| Pfizer INC. | $297.27 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $260.64 | 2020-2023 | Trintellix |
| Bausch Health US, LLC | $193.02 | 2020-2023 | Aplenzin, Wellbutrin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.11 | 2020-2023 | Trijardy Xr, Synjardy, Jardiance |
| Novartis Pharmaceuticals Corporation | $158.09 | 2022-2023 | |
| Lundbeck LLC | $125.91 | 2022-2023 | Vyepti |
| Glaxosmithkline, LLC. | $109.10 | 2021-2023 | Trelegy Ellipta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $67.86 | 2020-2023 | Tirosint, Licart |
| Daiichi Sankyo INC. | $47.28 | 2020-2022 | |
| Impel Pharmaceuticals INC. | $25.29 | 2022 | |
| Horizon Therapeutics Plc | $21.29 | 2023 | Krystexxa |
| Allergan, INC. | $18.29 | 2020 | |
| Abbott Laboratories | $17.96 | 2022 | |
| Eisai INC. | $16.52 | 2021 | |
| Axsome Therapeutics, INC. | $15.37 | 2023 | Auvelity |
| Idorsia Pharmaceuticals US INC | $13.91 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $12.29 | 2021 | |
| Sumitomo Pharma America, INC. | $8.25 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Summers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.